Dare Bioscience, Inc. Capital Expenditures Incurred but Not yet Paid
Dare Bioscience, Inc. (DARE) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-03-26
- Dare Bioscience, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was $0.00.
- Dare Bioscience, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was -$330.20K, a 148.84% decline year-over-year.
- Dare Bioscience, Inc. capital expenditures incurred but not yet paid for the quarter ending 2024-12-31 was -$175.81K.
- Dare Bioscience, Inc. capital expenditures incurred but not yet paid for the quarter ending 2024-09-30 was $676.04K.
- Dare Bioscience, Inc. capital expenditures incurred but not yet paid for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Dare Bioscience, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $500.23K.
- Dare Bioscience, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $0.00.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month | Capital Expenditures Incurred but Not yet Paid 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$330.20K derived: sum of 2 quarters · filed 2026-03-26 | $0.00 10-K · filed 2026-03-26 | ||
| 2025-09-30 | -$330.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $330.20K 10-Q · filed 2025-08-14 | ||||
| 2024-12-31 | -$175.81K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $500.23K derived: sum of 2 quarters · filed 2026-03-26 | $500.23K 10-K · filed 2026-03-26 | $749.04K 10-K · filed 2025-03-31 | |
| 2024-09-30 | $676.04K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $676.04K 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-14 | ||||
| 2023-12-31 | $0.00 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |